DFTX · Definium Therapeutics Inc
United States · RS rating 65 · As of 2026-11-03
| Price | 33.41 USD |
|---|---|
| 1-day change | +2.9% |
| RS rating (overall / 1M / 3M / 12M) | 65 / 39 / 26 / 96 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 31 / 27 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -102.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +31.0% |
| Market cap (USD) | $2.3B |